Abstracts tagged "SLE"

Abstract Number: 672 • 2019 ACR/ARP Annual Meeting
Mouse SLE Studies Do Not Describe Human SLE
Ecem Sevim¹, Linjia Jia ², David Fernandez ³ and Michael Lockshin ⁴, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Mary Kirkland Center for Lupus Research, New York, NY, ⁴Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: Although mouse models of systemic lupus erythematosus (SLE) are useful proxies for human illness, they are heterogeneous, and publications about mouse SLE may not…
Abstract Number: 1024 • 2019 ACR/ARP Annual Meeting
Lysosome Defects in SLE Promote the Accumulation of Nuclear Antigens on the Surface of Hematopoietic Cells
Sun Ah Kang¹, Jennifer Rogers ², Saira Sheikh ³, Megan Clowse ², Lisa Criscione-Schreiber ² and Barb Vilen ⁴, ¹University of NOrth Carolina at Chapel Hlil, Chapel Hill, NC, ²Duke University, Durham, ³University of North Carolina, Chapel Hill, NC, ⁴University of North Carolina CHapel Hill, Chapel Hill, NC
Background/Purpose: Impaired clearance of cell debris allows nuclear self-antigens such as DNA to accumulate, bind autoreactive IgG and form immune complexes (IgG-ICs) in SLE. We…
Abstract Number: 1579 • 2019 ACR/ARP Annual Meeting
Presence of Antiphospholipid Antibodies in Patients with SLE and Venous Thromboembolic Events of African American and Caucasian Race
Elena Gkrouzman¹, Julia Davis-Porada ¹, Mary Peng ² and Kyriakos Kirou ², ¹Hospital for Special Surgery, New York, ²Hospital for Special Surgery, New York, NY
Background/Purpose: Risk of thrombosis is elevated in patients with systemic lupus erythematosus (SLE) compared to healthy individuals, especially during the first year after diagnosis. The…
Abstract Number: 2034 • 2019 ACR/ARP Annual Meeting
Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- Double Negative (DN) T Cell Subsets in Lupus-prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement
Yi Li¹, Hao Li ², Shui Lian Yu ³, Vasileios Kyttaris ⁴ and George Tsokos ⁴, ¹BIDMC, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, ³The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (People's Republic), ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: We have previously shown that DN T cells are expanded in both lupus-prone mice and patients with SLE and we have demonstrated that this…
Abstract Number: 97 • 2018 ACR/ARHP Annual Meeting
Enhanced IFN-α Production By Plasmacytoid Dendritic Cells Is Associated with Increased Toll-like Receptor 7 Retention in the Lysosomes and Exosure to Type I IFN in Systemic Lupus Erythematosus
Goh Murayama¹, Asako Chiba², Ayako Makiyama², Ken Yamaji¹, Naoto Tamura¹ and Sachiko Miyake², ¹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Immunology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Type I interferon(IFN) appears to contribute to the development of systemic lupus erythematosus (SLE). Overexpression of type I IFN regulated genes has been reported…
Abstract Number: 753 • 2018 ACR/ARHP Annual Meeting
Young SLE Patients Have Higher Coronary Artery Calcium Scores Compared with Population Controls
Yevgeniya Gartshteyn¹, Genna Braverman², Sharan Mahtani³, Kayla Neville⁴, George Danias⁴, Laura Geraldino-Pardilla⁵, Sabahat Bokhari⁶ and Anca Askanase⁷, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Internal Medicine, Columbia University Medical Center, New York, NY, ³College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom, ⁴Rheumatology, Columbia University Medical Center, New York, NY, ⁵Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁶Cardiology, Columbia University, NY, NY, ⁷Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of death in systemic lupus erythematosus (SLE). The coronary artery calcium (CAC) score is a surrogate for…
Abstract Number: 1098 • 2018 ACR/ARHP Annual Meeting
Comparative Analysis of the Total Proteome of the Skin Lesions from Cutaneous Lupus Erythematosus (CLE) and Dermatomyositis (DM)
Timothy B. Niewold¹, Alexander Meves², Julia S. Lehman³, Karin Popovic-Silwerfeldt⁴, Cristine Charlesworth⁵, Marie Wahren-Herlenius⁶, Elisabet Svenungsson⁷ and Vilija Oke⁸, ¹Colton Center for Autoimmunity, New York University, New York, NY, ²Cancer Cenetr, Dermatology, Mayo Clinic, Rochester, MN, ³Pathology and Dermatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ⁴Department of Clinical Sciences, Dermatology Clinic, Danderyds Hospital,, Stockholm, Sweden, ⁵Mayo Clinic, Rochester, MN, ⁶Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁷Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁸Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are autoimmune diseases. The histopathological pattern of skin involvement can be similar, i.e. interface dermatitis, but the…
Abstract Number: 2089 • 2018 ACR/ARHP Annual Meeting
The Differential Impact of the Abrogation of the Costimulatory Molecule CD137 Ligand on Renal and Cerebral Manifestations in C57BL/6.Faslpr-/- mice
Anselm Mak¹, Bhushan Dharmadhikari², Lik Wei Wong², Saji Kumar Sreedharan² and Herbert Schwarz², ¹Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Background/Purpose: Costimulatory molecules which mediate cross-talks between leukocytes, have been identified to play a pathogenetic pivotal role in systemic lupus erythematosus (SLE). Abrogation of the…
Abstract Number: 2356 • 2018 ACR/ARHP Annual Meeting
Perceptions, Incentives, and Barriers to Clinical Trial Participation: Qualitative Evaluation of Lupus Patients, Enriched for Minority Participants
Cristina Arriens¹, Fredonna Carthen², D'Angelo Grant², Paul Kamp¹, Stan Kamp¹, Katherine Thanou¹, Teresa Aberle¹, Eliza Chakravarty¹, Judith A. James³, Joan T. Merrill¹ and Motolani E. Ogunsanya⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, OKLAHOMA CITY, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Although SLE disproportionately affects minority racial groups, they are significantly under-represented in clinical trials. This may lead to false, underpowered conclusions in race-based sub-group…
Abstract Number: 102 • 2018 ACR/ARHP Annual Meeting
Estrogen Controls the Expression of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in Human T Lymphocytes Via Transcriptional and Post-Transcriptional Mechanisms
Julian F. Oviedo¹, Elena N. Cravens¹ and Vaishali R. Moulton^2,3, ¹Beth Israel Deaconess Medical Center, Harvard Medical School, Medicine/Rheumatology, Boston, MA, ²Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ³Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic debilitating autoimmune disease that primarily afflicts women in the childbearing years. Female hormones especially estrogen are implicated…
Abstract Number: 758 • 2018 ACR/ARHP Annual Meeting
Cutaneous Lupus Erythematosus Patients with a Negative ANA Meeting Acr and/or SLICC Criteria for Systemic Lupus Erythematosus
Meera Tarazi¹, Carolyn Kushner², Rebecca Gaffney² and Victoria P. Werth³, ¹Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ²Dermatology, University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a disorder that is heterogeneous and can be difficult to diagnose. One hallmark of the disease is the presence…
Abstract Number: 1099 • 2018 ACR/ARHP Annual Meeting
Ongoing DNA Damage, Chromatin Deregulation and Defective DNA Damage Response in Systemic Autoimmune Rheumatic Diseases
Maria Pappa¹, Nikolaos I. Vlachogiannis¹, Alexandra Argyriou¹, Vassilis L. Souliotis² and Petros Sfikakis³, ¹National Kapodistrian University of Athens Medical School, Athens, Greece, First Department of Propaedeutic and Internal Medicine & Rheumatology Unit, National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ²National Hellenic Research Foundation, Athens, Greece, Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece, Athens, Greece, ³Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Athens University Medical School, Athens, Greece
Background/Purpose: Recent data highlight that patients with Systemic Lupus Erythematosus (SLE) have defects in two main DNA repair pathways, namely nucleotide excision repair (NER) and…
Abstract Number: 2091 • 2018 ACR/ARHP Annual Meeting
Mucosal-Associated Invariant T (MAIT) Cells As a Potential Therapeutic Target for Systemic Lupus Erythematosus
Goh Murayama¹, Asako Chiba², Atsushi Nomura³, Hirofumi Amano¹, Ken Yamaji¹, Naoto Tamura¹ and Sachiko Miyake^4,5, ¹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Juntendo Univ Sch of Med, Juntendo University School of Medicine, Tokyo, Japan, ³JUNTENDO UNIVERSITY SCHOOL OF MEDICINE, Tokyo, Japan, ⁴Division of Immunology/NCNP, Natl Institute of Neuroscience, Kodaira Tokyo, Japan, ⁵Immunology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by the nonpolymorphic MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain:…
Abstract Number: 2436 • 2018 ACR/ARHP Annual Meeting
The Impact of Different Classes of Lupus Nephritis on Maternal and Fetal Outcomes
Bruna Costa Rodrigues¹, Marcela Ignacchiti Lacerda¹, Guilherme Ramires de Jesus², Flavia Cunha dos Santos², Nilson Ramires de Jesus², Roger Abramino Levy^1,3 and Evandro Mendes Klumb¹, ¹Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Immunology and Inflammation, GlaxoSmithKline, Upper Providence, PA
Background/Purpose: During pregnancy, history of lupus nephritis (LN) has been independently associated with increased risk of adverse maternal and fetal outcomes, which are even more…
Abstract Number: 104 • 2018 ACR/ARHP Annual Meeting
Identification of a Gut Pathobiont Immunostimulatory Lipoglycan Antigen Linked to Lupus Nephritis
Gregg Silverman¹, Nicolas Gisch², Aidana Omarbekova³ and Doua F. Azzouz⁴, ¹Department of Medicine, New York University School of Medicine, New York, NY, ²Research Center Borstel, Schleswig-Holstein, Germany, ³New York University School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY
Background/Purpose: A transmissible agent has long been suspected in SLE. In a discovery cohort we found that,compared with healthy subjects, Lupus patients had a five-fold…

« Previous Page
1
…
4
5
6
7
8
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.